Cereblon–Cyclin-dependent kinase 2 (CRBN–CDK2) (CRBN–CDK2)

The CRBN–CDK2 target refers to the therapeutic degradation axis involving the recruitment of the Cereblon (CRBN) E3 ubiquitin ligase to induce the selective proteasomal degradation of Cyclin-dependent kinase 2 (CDK2) (UniProt: Q96SW2, P24941). CDK2 is a critical serine/threonine kinase that regulates the eukaryotic cell cycle, specifically governing the G1 to S phase transition through its interaction with E-type cyclins (PubMed: 32814062). In various malignancies, such as CCNE1-amplified breast and ovarian cancers, CDK2 is hyperactivated, making it a high-priority oncology target (PubMed: 34644538). By utilizing Proteolysis Targeting Chimeras (PROTACs), researchers can bridge CRBN and CDK2, leading to the polyubiquitination of CDK2 and its subsequent degradation by the 26S proteasome (PubMed: 33434033). This approach offers a potential advantage over traditional kinase inhibitors by completely removing the protein scaffold, which may overcome resistance mechanisms and provide more durable inhibition of oncogenic signaling. Selective CDK2 degraders like CPS2 have demonstrated the ability to induce cell cycle arrest and apoptosis in sensitive cancer cell lines while sparing other CDKs (PubMed: 32814062). Therapeutic challenges include the potential for teratogenicity due to the CRBN-binding moiety and the risk of hematologic toxicities common to cell cycle inhibitors (StatPearls: Thalidomide). Monitoring CDK2 and CRBN expression levels, as well as CCNE1 amplification status, is essential for predicting the efficacy of these bifunctional degraders in clinical settings.

Other names

CRBN-CDK2 degradation axisCereblon-CDK2 complexCDK2-CRBNCereblonCyclin-dependent kinase 2

Targeted protein degradation (TPD) via the recruitment of the Cereblon (CRBN) E3 ubiquitin ligase to Cyclin-dependent kinase 2 (CDK2) using a Proteolysis Targeting Chimera (PROTAC), leading to polyubiquitination and subsequent 26S proteasomal degradation.